Patents by Inventor Ralph Schwall

Ralph Schwall has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20200048362
    Abstract: The application concerns methods of treatment using anti-ErbB receptor antibody-maytansinoid conjugates, and articles of manufacture suitable for use in such methods. In particular, the invention concerns ErbB receptor-directed cancer therapies, using anti-ErbB receptor antibody-maytansinoid conjugates.
    Type: Application
    Filed: February 19, 2019
    Publication date: February 13, 2020
    Inventors: Walter Blattler, Ravi V.J. Chari, Mark Sliwkowski, Sharon Erickson, Ralph Schwall
  • Publication number: 20170106097
    Abstract: The application concerns methods of treatment using anti-ErbB receptor antibody-maytansinoid conjugates, and articles of manufacture suitable for use in such methods. In particular, the invention concerns ErbB receptor-directed cancer therapies, using anti-ErbB receptor antibody-maytansinoid conjugates.
    Type: Application
    Filed: June 1, 2016
    Publication date: April 20, 2017
    Inventors: Walter BLATTLER, Ravi V.J. Chari, Mark Sliwkowski, Sharon Erickson, Ralph Schwall
  • Publication number: 20150110816
    Abstract: The application concerns methods of treatment using anti-ErbB receptor antibody-maytansinoid conjugates, and articles of manufacture suitable for use in such methods. In particular, the invention concerns ErbB receptor-directed cancer therapies, using anti-ErbB receptor antibody-maytansinoid conjugates.
    Type: Application
    Filed: June 4, 2014
    Publication date: April 23, 2015
    Applicants: GENENTECH, INC., IMMUNOGEN INC.
    Inventors: Walter BLATTLER, Ravi V.J. CHARI, Mark SLIWKOWSKI, Sharon ERICKSON, Ralph SCHWALL
  • Publication number: 20140212411
    Abstract: The application concerns methods of treatment using anti-ErbB receptor antibody-maytansinoid conjugates, and articles of manufacture suitable for use in such methods. In particular, the invention concerns ErbB receptor-directed cancer therapies, using anti-ErbB receptor antibody-maytansinoid conjugates.
    Type: Application
    Filed: September 19, 2013
    Publication date: July 31, 2014
    Applicants: GENENTECH, INC., IMMUNOGEN, INC.
    Inventors: Walter BLATTLER, Ralph SCHWALL, Mark SLIWKOWSKI, Sharon ERICKSON, Ravi V.J. CHARI
  • Publication number: 20100136033
    Abstract: The application concerns methods of treatment using anti-ErbB receptor antibody-maytansinoid conjugates, and articles of manufacture suitable for use in such methods. In particular, the invention concerns ErbB receptor-directed cancer therapies, using anti-ErbB receptor antibody-maytansinoid conjugates.
    Type: Application
    Filed: October 30, 2009
    Publication date: June 3, 2010
    Applicant: IMMUNOGEN, INC.
    Inventors: Sharon Erickson, Ralph Schwall, Mark Sliwkowski, Walter Blattler
  • Patent number: 7575748
    Abstract: The application concerns methods of treatment using anti-ErbB receptor antibody-maytansinoid conjugates, and articles of manufacture suitable for use in such methods. In particular, the invention concerns ErbB receptor-directed cancer therapies, using anti-ErbB receptor antibody-maytansinoid conjugates.
    Type: Grant
    Filed: July 17, 2006
    Date of Patent: August 18, 2009
    Assignee: Genentech, Inc.
    Inventors: Sharon Erickson, Ralph Schwall, Mark Sliwkowski, Walter Blattler
  • Publication number: 20090041788
    Abstract: Methods of using synergistically effective amounts of Apo-2L receptor agonists and CPT-11 to induce apoptosis and suppress growth of cancer cells, are provided.
    Type: Application
    Filed: October 14, 2008
    Publication date: February 12, 2009
    Applicant: Genentech, Inc.
    Inventors: Avi J. Ashkenazi, Mark Benyunes, Ralph Schwall
  • Publication number: 20080226659
    Abstract: The application concerns methods of treatment using anti-ErbB receptor antibody-maytansinoid conjugates, and articles of manufacture suitable for use in such methods. In particular, the invention concerns ErbB receptor-directed cancer therapies, using anri-ErbB receptor antibody-maytansinoid conjugates.
    Type: Application
    Filed: December 3, 2007
    Publication date: September 18, 2008
    Inventors: Sharon Erickson, Ralph Schwall, Mark Sliwkowski, Walter Blattler
  • Publication number: 20080063641
    Abstract: The invention provides methods and compositions comprising a novel stabilized monovalent antibody fragment.
    Type: Application
    Filed: October 3, 2006
    Publication date: March 13, 2008
    Inventors: Arthur Huang, Ralph Schwall, Daniel Yansura
  • Publication number: 20080044415
    Abstract: Hepatocyte growth factor (HGF) receptor antagonists are provided. The HGF receptor antagonists include HGF receptor antibodies and fragments thereof. The HGF receptor antagonists can be employed to block binding of HGF to HGF receptors or substantially inhibit HGF receptor activation. The HGF receptor antagonists may be included in pharmaceutical compositions, articles of manufacture, or kits. Methods of treating cancer using the HGF receptor antagonists are also provided.
    Type: Application
    Filed: October 31, 2006
    Publication date: February 21, 2008
    Inventors: Ralph Schwall, Kelly Tabor
  • Publication number: 20070026000
    Abstract: Methods of using synergistically effective amounts of Apo-2L receptor agonists and CPT-11 to induce apoptosis and suppress growth of cancer cells are provided.
    Type: Application
    Filed: September 29, 2006
    Publication date: February 1, 2007
    Applicant: Genentech, Inc.
    Inventors: Avi Ashkenazi, Mark Benyunes, Ralph Schwall
  • Publication number: 20060211612
    Abstract: Methods for enhancing angiogenesis in a mammal using hepatocyte growth factor (“HGF”) are provided. In the methods, HGF can be administered to mammals suffering from, for instance, vascular insufficiency or arterial occlusive disease. Articles of manufacture and kits containing HGF are also provided.
    Type: Application
    Filed: December 5, 2005
    Publication date: September 21, 2006
    Inventors: Napoleone Ferrara, Jeffrey Isner, Ralph Schwall
  • Patent number: 7097840
    Abstract: The application concerns methods of treatment using anti-ErbB receptor antibody-maytansinoid conjugates, and articles of manufacture suitable for use in such methods. In particular, the invention concerns ErbB receptor-directed cancer therapies, using anri-ErbB receptor antibody-maytansinoid conjugates.
    Type: Grant
    Filed: March 16, 2001
    Date of Patent: August 29, 2006
    Assignees: Genentech, Inc., Immunogen, Inc.
    Inventors: Sharon Erickson, Ralph Schwall, Mark Sliwkowski, Walter Blattler
  • Publication number: 20060177448
    Abstract: The present application describes using antagonists of matrix metalloproteases (MMPs), especially of MMP-15, for inhibiting HER2 shedding.
    Type: Application
    Filed: February 9, 2006
    Publication date: August 10, 2006
    Applicant: Genentech, Inc.
    Inventors: Kendall Carey, Ralph Schwall, Mark Sliwkowski, Gail Schwall
  • Publication number: 20050276812
    Abstract: The present invention relates to antibody-drug conjugate compounds of Formula I: Ab-(L-D)p??I where one or more maytansinoid drug moieties (D) are covalently linked by L to an antibody (Ab) which binds to an ErbB receptor, or which binds to one or more tumor-associated antigens or cell-surface receptors. These compounds may be used in methods of diagnosis or treatment of cancer, and other diseases and disorders.
    Type: Application
    Filed: May 31, 2005
    Publication date: December 15, 2005
    Applicant: Genentech, Inc.
    Inventors: Allen Ebens, Frederic Jacobson, Paul Polakis, Ralph Schwall, Mark Sliwkowski, Susan Spencer
  • Publication number: 20050250686
    Abstract: Methods for enhancing angiogenesis in a mammal using hepatocyte growth factor (“HGF”) are provided. In the methods, HGF can be administered to mammals suffering from, for instance, vascular insufficiency or arterial occlusive disease. Articles of manufacture and kits containing HGF are also provided.
    Type: Application
    Filed: August 19, 2003
    Publication date: November 10, 2005
    Inventors: Napoleone Ferrara, Jeffrey Isner, Ralph Schwall
  • Publication number: 20050227324
    Abstract: The invention provides methods and compositions comprising a novel stabilized monovalent antibody fragment.
    Type: Application
    Filed: December 17, 2004
    Publication date: October 13, 2005
    Inventors: Arthur Huang, Ralph Schwall, Daniel Yansura
  • Publication number: 20050089958
    Abstract: A novel cytokine, designated Apo-2 ligand, which induces mammalian cell apoptosis is provided. The Apo-2 ligand is believed to be a member of the TNF cytokine family. Compositions including Apo-2 ligand chimeras, nucleic acid encoding Apo-2 ligand, and antibodies to Apo-2 ligand are also provided. Methods of using Apo-2 ligand to induce apoptosis and to treat pathological conditions such as cancer, are further provided.
    Type: Application
    Filed: August 29, 2003
    Publication date: April 28, 2005
    Inventors: Avi Ashkenazi, Ralph Schwall
  • Publication number: 20040228868
    Abstract: Methods of using synergistically effective amounts of Apo-2L receptor agonists and CPT-11 to induce apoptosis and suppress growth of cancer cells are provided.
    Type: Application
    Filed: June 17, 2004
    Publication date: November 18, 2004
    Applicant: Genentech, Inc.
    Inventors: Avi J. Ashkenazi, Mark Benyunes, Ralph Schwall
  • Patent number: 6740739
    Abstract: A novel cytokine, designated Apo-2 ligand, which induces mammalian cancer cell apoptosis is provided. The Apo-2 ligand is believed to be a member of the TNF cytokine family. Compositions including Apo-2 ligand chimeras, nucleic acid encoding Apo-2 ligand, and antibodies to Apo-2 ligand are also provided. Methods of using Apo-2 ligand to induce apoptosis and to treat pathological conditions such as cancer, are further provided.
    Type: Grant
    Filed: June 26, 2000
    Date of Patent: May 25, 2004
    Assignee: Genentech, Inc.
    Inventors: Avi J. Ashkenazi, Robert F. Kelley, Mark P. O'Connell, Robert M. Pitti, Ralph A. Schwall